[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-001", "question": "A 74-year-old man presents with heart failure with preserved ejection fraction (HFpEF) and bilateral carpal tunnel syndrome. Echocardiography reveals a granular 'sparkling' appearance of the myocardium and increased wall thickness. A technetium-99m pyrophosphate (PYP) scan shows Grade 3 cardiac uptake (uptake > rib uptake). Serum immunofixation reveals a small IgG lambda monoclonal protein, and serum free light chain ratio is 1.8. Which of the following is the most appropriate next step in management to confirm the diagnosis?", "options": ["Initiate tafamidis therapy", "Perform TTR genetic testing", "Endomyocardial biopsy", "Abdominal fat pad aspiration", "Initiate bortezomib, cyclophosphamide, and dexamethasone"], "answer": "C", "answer_index": 2, "explanation": "While Grade 2/3 PYP uptake is highly specific for ATTR cardiac amyloidosis, this specificity drops significantly in the presence of a monoclonal gammopathy (MGUS). AL amyloidosis can occasionally show uptake on PYP scans. Therefore, in a patient with a positive PYP scan AND a monoclonal protein, a tissue biopsy (endomyocardial is gold standard if non-cardiac biopsy is negative or to avoid sampling error) is mandatory to distinguish ATTR from AL amyloidosis before starting treatment.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed). Verdict: The keyed answer C is not the best answer; the unique best answer is D. Key stem clues: elderly man, HFpEF, carpal tunnel, echocardiographic sparkling, Grade 3 PYP uptake, small IgG λ monoclonal protein, and FLC ratio 1.8. These raise suspicion for cardiac amyloidosis but also a concurrent monoclonal gammopathy, requiring tissue typing. Main logical issue: The item incorrectly identifies endomyocardial biopsy as the most appropriate next step. Current guidelines (ASNC 2023, ESC) recommend an initial non‑cardiac tissue biopsy (abdominal fat pad aspiration) in patients with positive PYP scan and monoclonal protein; endomyocardial biopsy is reserved for when non‑cardiac biopsy is negative or to avoid sampling error. This misalignment makes the item miskeyed and also underspecified because it does not acknowledge the preferred less‑invasive approach. Main medical accuracy issue: The answer key endorses an unnecessarily invasive procedure that is not the standard first step and could cause harm; the correct management is to obtain a tissue sample from an accessible site (fat pad) first. Minimal fix: Replace the key with option D and revise the rationale to state that abdominal fat pad aspiration is the recommended initial tissue biopsy to distinguish AL from ATTR before considering cardiac biopsy.\",\"medical_accuracy_score\":2,\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer C is not the best answer; the unique best answer is D. Key stem clues: elderly man, HFpEF, carpal tunnel, echocardiographic sparkling, Grade 3 PYP uptake, small IgG λ monoclonal protein, and FLC ratio 1.8. These raise suspicion for cardiac amyloidosis but also a concurrent monoclonal gammopathy, requiring tissue typing. Main logical issue: The item incorrectly identifies endomyocardial biopsy as the most appropriate next step. Current guidelines (ASNC 2023, ESC) recommend an initial non‑cardiac tissue biopsy (abdominal fat pad aspiration) in patients with positive PYP scan and monoclonal protein; endomyocardial biopsy is reserved for when non‑cardiac biopsy is negative or to avoid sampling error. This misalignment makes the item miskeyed and also underspecified because it does not acknowledge the preferred less‑invasive approach. Main medical accuracy issue: The answer key endorses an unnecessarily invasive procedure that is not the standard first step and could cause harm; the correct management is to obtain a tissue sample from an accessible site (fat pad) first. Minimal fix: Replace the key with option D and revise the rationale to state that abdominal fat pad aspiration is the recommended initial tissue biopsy to distinguish AL from ATTR before considering cardiac biopsy.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-002", "question": "A 24-year-old male presents with recurrent fevers, livedo racemosa, and acute left hemiparesis. MRI shows a lacunar infarct in the internal capsule. Angiography reveals a 'beads-on-a-string' appearance in the mesenteric and renal arteries. Laboratory evaluation shows low serum IgM and IgG levels. Genetic testing confirms a biallelic loss-of-function mutation in ADA2. Which of the following is the most appropriate maintenance therapy?", "options": ["Cyclophosphamide", "Rituximab", "Etanercept", "Prednisone monotherapy", "Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "The patient has Deficiency of Adenosine Deaminase 2 (DADA2), which mimics Polyarteritis Nodosa (PAN) but is distinct due to its association with early-onset strokes and hypogammaglobulinemia. Unlike classic PAN, which is treated with cyclophosphamide, DADA2 is driven by TNF-alpha dysregulation. TNF inhibitors (like etanercept) are the treatment of choice and are highly effective in preventing recurrent strokes, whereas cyclophosphamide is often ineffective.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a young adult with early‑onset lacunar stroke, livedo racemosa, visceral artery ‘beads‑on‑a‑string’ angiography, hypogammaglobulinemia, and a biallelic ADA2 loss‑of‑function mutation—classic for DADA2. The question asks for the most appropriate maintenance therapy. The key discriminating clue is the genetic confirmation of DADA2, a TNF‑α‑driven vasculopathy. The correct answer, etanercept, is a TNF inhibitor that has demonstrated efficacy in preventing recurrent strokes and vasculitic flares in DADA2; it is the recommended maintenance agent. Cyclophosphamide, the standard for polyarteritis nodosa, is ineffective and carries undue toxicity in DADA2. Rituximab targets B cells and has no role in this TNF‑mediated disease. Prednisone monotherapy does not provide durable disease control and is insufficient as maintenance. Plasma exchange is not supported by evidence. No internal contradictions exist, and the options are mutually exclusive, allowing a single best answer. The item is medically accurate and aligns with current consensus (e.g., 2020 DADA2 treatment guidelines). Minor wording could be clarified (e.g., specifying ‘maintenance’ after induction), but the item is sound as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a young adult with early‑onset lacunar stroke, livedo racemosa, visceral artery ‘beads‑on‑a‑string’ angiography, hypogammaglobulinemia, and a biallelic ADA2 loss‑of‑function mutation—classic for DADA2. The question asks for the most appropriate maintenance therapy. The key discriminating clue is the genetic confirmation of DADA2, a TNF‑α‑driven vasculopathy. The correct answer, etanercept, is a TNF inhibitor that has demonstrated efficacy in preventing recurrent strokes and vasculitic flares in DADA2; it is the recommended maintenance agent. Cyclophosphamide, the standard for polyarteritis nodosa, is ineffective and carries undue toxicity in DADA2. Rituximab targets B cells and has no role in this TNF‑mediated disease. Prednisone monotherapy does not provide durable disease control and is insufficient as maintenance. Plasma exchange is not supported by evidence. No internal contradictions exist, and the options are mutually exclusive, allowing a single best answer. The item is medically accurate and aligns with current consensus (e.g., 2020 DADA2 treatment guidelines). Minor wording could be clarified (e.g., specifying ‘maintenance’ after induction), but the item is sound as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-003", "question": "A 64-year-old male presents with a 1-year history of progressive gait instability, dysarthria, and dysphagia. His wife reports he has severe insomnia, stridor during sleep, and acts out his dreams. Polysomnography confirms obstructive sleep apnea and complex behaviors during both REM and NREM sleep. MRI brain is unremarkable. Which of the following antibodies is most likely to be positive?", "options": ["Anti-Hu", "Anti-Ma2", "Anti-LGI1", "Anti-IgLON5", "Anti-DPPX"], "answer": "D", "answer_index": 3, "explanation": "Anti-IgLON5 disease is a distinct tauopathy characterized by a unique sleep disorder (parasomnias in both REM and NREM sleep, stridor, OSA) combined with bulbar dysfunction and gait instability. While Anti-Ma2 is associated with brainstem/diencephalic involvement and sleepiness, the specific combination of stridor, NREM parasomnias, and bulbar palsy is pathognomonic for Anti-IgLON5.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\": \",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"4\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ": ", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-004", "question": "A 68-year-old male presents with fever of unknown origin, 15 kg weight loss, and fatigue 4 years after undergoing aortic valve replacement. Labs reveal pancytopenia and elevated liver enzymes. TTE and TEE show no vegetations. PET-CT demonstrates hypermetabolic activity in the spleen and bone marrow. Bone marrow biopsy reveals non-caseating granulomas. Standard blood cultures are negative. Which of the following is the most likely etiology?", "options": ["Sarcoidosis", "Culture-negative endocarditis (HACEK group)", "Mycobacterium chimaera", "Tropheryma whipplei", "Late-onset prosthetic valve thrombosis"], "answer": "C", "answer_index": 2, "explanation": "This is the classic presentation of disseminated *Mycobacterium chimaera* infection associated with contaminated heater-cooler units used during cardiopulmonary bypass. The incubation period can be several years. It presents with systemic symptoms, cytopenias, and granulomatous inflammation (often misdiagnosed as sarcoidosis). Diagnosis requires specific mycobacterial blood cultures or tissue PCR.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: The keyed answer C is the correct best answer. Key discriminating clues: remote cardiopulmonary bypass surgery (4 years prior), systemic symptoms with pancytopenia, non-caseating granulomas on bone marrow biopsy, negative standard blood cultures, and absence of vegetations on echocardiography. This constellation is pathognomonic for disseminated Mycobacterium chimaera infection from contaminated heater-cooler units. Alternative options are appropriately excluded: sarcoidosis lacks the specific surgical exposure; HACEK endocarditis would typically demonstrate vegetations; Tropheryma whipplei usually presents with GI/arthritic symptoms and rarely granulomas; prosthetic valve thrombosis causes mechanical complications rather than systemic granulomatous disease. The item is logically sound with a single unambiguous best answer. Medical accuracy is excellent: M. chimaera infection is a recognized complication of cardiopulmonary bypass with precisely the described incubation period, culture negativity, and granulomatous inflammation. No contradictions or underspecification. Minimal fix: None required; item is board-ready.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: The keyed answer C is the correct best answer. Key discriminating clues: remote cardiopulmonary bypass surgery (4 years prior), systemic symptoms with pancytopenia, non-caseating granulomas on bone marrow biopsy, negative standard blood cultures, and absence of vegetations on echocardiography. This constellation is pathognomonic for disseminated Mycobacterium chimaera infection from contaminated heater-cooler units. Alternative options are appropriately excluded: sarcoidosis lacks the specific surgical exposure; HACEK endocarditis would typically demonstrate vegetations; Tropheryma whipplei usually presents with GI/arthritic symptoms and rarely granulomas; prosthetic valve thrombosis causes mechanical complications rather than systemic granulomatous disease. The item is logically sound with a single unambiguous best answer. Medical accuracy is excellent: M. chimaera infection is a recognized complication of cardiopulmonary bypass with precisely the described incubation period, culture negativity, and granulomatous inflammation. No contradictions or underspecification. Minimal fix: None required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-005", "question": "A 31-year-old female presents with amenorrhea 4 months after a full-term delivery. Ultrasound reveals a 4 cm echogenic mass in the myometrium. Serum beta-hCG is 120 IU/L. Immunohistochemistry of a biopsy specimen shows diffuse positivity for human placental lactogen (hPL) and Ki-67 index of 15%. Staging workup is negative for metastasis. What is the treatment of choice?", "options": ["Methotrexate and Folinic Acid", "Actinomycin D", "EMA-CO regimen", "Hysterectomy", "Pembrolizumab"], "answer": "D", "answer_index": 3, "explanation": "The diagnosis is Placental Site Trophoblastic Tumor (PSTT), distinguished from choriocarcinoma by low beta-hCG, strong hPL positivity, and origin from intermediate trophoblasts. Unlike choriocarcinoma, PSTT is relatively resistant to chemotherapy. For localized (Stage I) disease, hysterectomy is the primary and definitive treatment. Chemotherapy is reserved for metastatic or high-risk disease.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The stem's key discriminators—amenorrhea 4 months postpartum, 4 cm myometrial mass, low β-hCG (120 IU/L), diffuse hPL positivity, Ki-67 index of 15%, and negative metastasis—unambiguously establish a diagnosis of localized placental site trophoblastic tumor (PSTT). This immunophenotype and proliferative index distinguish PSTT from choriocarcinoma (high β-hCG, hPL-negative, Ki-67 >50%) and other gestational trophoblastic neoplasias. For Stage I PSTT, hysterectomy is the definitive treatment of choice due to inherent chemoresistance; systemic therapy is ineffective for localized disease. Options A-C (methotrexate, actinomycin D, EMA-CO) are standard for other GTN subtypes but inappropriate here. Pembrolizumab (E) is not first-line. All distractors are clearly inferior, enabling clean discrimination. No internal contradictions or missing critical details. Medical accuracy is gold-standard: the diagnostic criteria, immunohistochemical profile, Ki-67 range, and management align precisely with current FIGO/ASCO guidelines and board expectations. The scenario is clinically realistic and teaching-point focused. Minimal fix: none required; item is examination-ready.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The stem's key discriminators—amenorrhea 4 months postpartum, 4 cm myometrial mass, low β-hCG (120 IU/L), diffuse hPL positivity, Ki-67 index of 15%, and negative metastasis—unambiguously establish a diagnosis of localized placental site trophoblastic tumor (PSTT). This immunophenotype and proliferative index distinguish PSTT from choriocarcinoma (high β-hCG, hPL-negative, Ki-67 >50%) and other gestational trophoblastic neoplasias. For Stage I PSTT, hysterectomy is the definitive treatment of choice due to inherent chemoresistance; systemic therapy is ineffective for localized disease. Options A-C (methotrexate, actinomycin D, EMA-CO) are standard for other GTN subtypes but inappropriate here. Pembrolizumab (E) is not first-line. All distractors are clearly inferior, enabling clean discrimination. No internal contradictions or missing critical details. Medical accuracy is gold-standard: the diagnostic criteria, immunohistochemical profile, Ki-67 range, and management align precisely with current FIGO/ASCO guidelines and board expectations. The scenario is clinically realistic and teaching-point focused. Minimal fix: none required; item is examination-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-006", "question": "A 40-year-old male with a known diagnosis of Brugada syndrome presents to the ER in electrical storm, having received 4 appropriate ICD shocks for ventricular fibrillation in the past hour. He is currently conscious but anxious. Vital signs are BP 110/70, HR 90. Which pharmacologic agent is most appropriate to suppress the arrhythmia?", "options": ["Intravenous Amiodarone", "Intravenous Lidocaine", "Intravenous Isoproterenol", "Intravenous Procainamide", "Intravenous Metoprolol"], "answer": "C", "answer_index": 2, "explanation": "In Brugada syndrome electrical storm, the goal is to decrease the ST-segment elevation and dispersion. Isoproterenol (a beta-agonist) increases heart rate and calcium current, normalizing the ST segment and suppressing VF. Quinidine is the oral alternative. Amiodarone, beta-blockers, and sodium channel blockers (Procainamide, Lidocaine) are contraindicated or ineffective as they can unmask or exacerbate the Brugada pattern.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict on keyed answer: Correct best. The stem asks for the most appropriate pharmacologic agent to suppress ventricular fibrillation in a Brugada syndrome patient with electrical storm. Key discriminating findings: Brugada syndrome, electrical storm (4 VF shocks), conscious, HR 90. The pathophysiology involves ST-segment elevation due to reduced sodium current; increasing heart rate and calcium current (via beta-agonism) normalizes the ST segment and suppresses VF. Isoproterenol is the established first-line IV therapy for electrical storm in Brugada syndrome. The keyed answer (C) is directly supported by current consensus and guidelines (e.g., HRS/EHRA/APHRS 2013 expert consensus). Alternative evaluation: A) Amiodarone is ineffective and may worsen the substrate; B) Lidocaine (sodium channel blocker) can exacerbate the Brugada pattern; D) Procainamide is contraindicated as it unmasks/worsens the Brugada ECG pattern; E) Metoprolol (beta-blocker) is contraindicated because it reduces heart rate and can precipitate VF. No logical issues: the vignette provides sufficient detail, the options are mutually exclusive, and the key is unambiguous. Medical accuracy: fully aligned with contemporary management of Brugada electrical storm. No contradictions or underspecification.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict on keyed answer: Correct best. The stem asks for the most appropriate pharmacologic agent to suppress ventricular fibrillation in a Brugada syndrome patient with electrical storm. Key discriminating findings: Brugada syndrome, electrical storm (4 VF shocks), conscious, HR 90. The pathophysiology involves ST-segment elevation due to reduced sodium current; increasing heart rate and calcium current (via beta-agonism) normalizes the ST segment and suppresses VF. Isoproterenol is the established first-line IV therapy for electrical storm in Brugada syndrome. The keyed answer (C) is directly supported by current consensus and guidelines (e.g., HRS/EHRA/APHRS 2013 expert consensus). Alternative evaluation: A) Amiodarone is ineffective and may worsen the substrate; B) Lidocaine (sodium channel blocker) can exacerbate the Brugada pattern; D) Procainamide is contraindicated as it unmasks/worsens the Brugada ECG pattern; E) Metoprolol (beta-blocker) is contraindicated because it reduces heart rate and can precipitate VF. No logical issues: the vignette provides sufficient detail, the options are mutually exclusive, and the key is unambiguous. Medical accuracy: fully aligned with contemporary management of Brugada electrical storm. No contradictions or underspecification.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-007", "question": "A 32-year-old female presents with subacute confusion, bilateral hearing loss, and visual field deficits. MRI brain shows multiple T2 hyperintense lesions in the corpus callosum ('snowballs') and periventricular white matter. Fluorescein angiography reveals multiple branch retinal artery occlusions (BRAO). CSF shows mild pleocytosis and elevated protein but no oligoclonal bands. What is the most likely diagnosis?", "options": ["Multiple Sclerosis", "CADASIL", "Susac Syndrome", "Primary CNS Angiitis", "Mitochondrial Encephalomyopathy (MELAS)"], "answer": "C", "answer_index": 2, "explanation": "Susac Syndrome is a rare autoimmune endotheliopathy characterized by the clinical triad of encephalopathy, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. The MRI finding of 'snowball' lesions in the corpus callosum is highly characteristic. It is often misdiagnosed as MS, but the presence of BRAO and callosal lesions (rather than callososeptal interface lesions) distinguishes it.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The stem presents a classic triad of encephalopathy, bilateral hearing loss, and branch retinal artery occlusions (BRAO) in a young woman, with MRI showing characteristic 'snowball' T2 hyperintense lesions in the corpus callosum. These findings uniquely point to Susac syndrome, an autoimmune endotheliopathy. CSF pleocytosis without oligoclonal bands further distinguishes it from multiple sclerosis. Key discriminating clues include: (1) clinical triad, (2) specific MRI pattern, and (3) angiographic BRAO. Alternative options are appropriately excluded: MS lacks BRAO and typically shows oligoclonal bands; CADASIL has different MRI distribution (anterior temporal/external capsule) and no BRAO; primary CNS angiitis lacks the triad and characteristic MRI; MELAS has stroke-like episodes but not BRAO. No logical contradictions or ambiguities prevent a single best answer. Medical content is accurate and board-relevant. Minimal fix: specify 'sensorineural' hearing loss for absolute clarity, though this is strongly implied by the triad context.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The stem presents a classic triad of encephalopathy, bilateral hearing loss, and branch retinal artery occlusions (BRAO) in a young woman, with MRI showing characteristic 'snowball' T2 hyperintense lesions in the corpus callosum. These findings uniquely point to Susac syndrome, an autoimmune endotheliopathy. CSF pleocytosis without oligoclonal bands further distinguishes it from multiple sclerosis. Key discriminating clues include: (1) clinical triad, (2) specific MRI pattern, and (3) angiographic BRAO. Alternative options are appropriately excluded: MS lacks BRAO and typically shows oligoclonal bands; CADASIL has different MRI distribution (anterior temporal/external capsule) and no BRAO; primary CNS angiitis lacks the triad and characteristic MRI; MELAS has stroke-like episodes but not BRAO. No logical contradictions or ambiguities prevent a single best answer. Medical content is accurate and board-relevant. Minimal fix: specify 'sensorineural' hearing loss for absolute clarity, though this is strongly implied by the triad context.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-008", "question": "A 29-year-old male who has sex with men presents with severe proctitis, tenesmus, and rectal bleeding. Rectal swab NAAT is positive for *Chlamydia trachomatis*. He was treated with Doxycycline 100 mg BID for 7 days with no improvement. His partner recently returned from Europe. Which of the following is the most appropriate management?", "options": ["Repeat Doxycycline 100 mg BID for 7 days", "Azithromycin 1 g single dose", "Ceftriaxone 500 mg IM single dose", "Extend Doxycycline 100 mg BID to complete a 21-day course", "Moxifloxacin 400 mg daily for 14 days"], "answer": "D", "answer_index": 3, "explanation": "Severe proctitis in MSM with a positive Chlamydia test should raise suspicion for Lymphogranuloma Venereum (LGV), caused by L1, L2, or L3 serovars. LGV requires a prolonged course of doxycycline (21 days) compared to non-LGV chlamydia (7 days). Standard treatment failure and severe symptoms (bleeding/tenesmus) strongly support a diagnosis of LGV.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\":Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. Key stem clues: MSM with severe proctitis, tenesmus, rectal bleeding, positive Chlamydia trachomatis NAAT, treatment failure after 7 days doxycycline, partner travel from Europe. These findings raise suspicion for LGV, which requires 21 days doxycycline. However, the vignette lacks confirmatory testing (e.g., genotyping for L1-L3 serovars) or explicit clinical criteria that distinguish LGV from severe non-LGV chlamydial proctitis. While LGV is plausible, severe non-LGV proctitis can also present similarly and may require extended therapy. Option D (21-day doxycycline) is a defensible empiric choice for suspected LGV. However, Option E (moxifloxacin 400 mg daily for 14 days) is also a CDC-recommended alternative for LGV when doxycycline is contraindicated or not tolerated, making it a reasonable alternative best answer. The item is underspecified because without stating doxycycline intolerance/contraindication or providing LGV confirmation, both D and E are defensible. No internal contradictions. Medical accuracy: aligns with CDC STI guidelines that LGV requires 21-day doxycycline and moxifloxacin is an alternative. Minor issue: does not mention need for genotyping or HIV/MSM screening context. Minimal fix: Add clause 'Genotyping confirms L1 serovar' or 'Doxycycline is the preferred agent per guidelines' to eliminate Option E as a competitor.\",\"logical_false_reason\":\"U\",\"logical_validity\":false,\"medical_accuracy_score\":\"4\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ":Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. Key stem clues: MSM with severe proctitis, tenesmus, rectal bleeding, positive Chlamydia trachomatis NAAT, treatment failure after 7 days doxycycline, partner travel from Europe. These findings raise suspicion for LGV, which requires 21 days doxycycline. However, the vignette lacks confirmatory testing (e.g., genotyping for L1-L3 serovars) or explicit clinical criteria that distinguish LGV from severe non-LGV chlamydial proctitis. While LGV is plausible, severe non-LGV proctitis can also present similarly and may require extended therapy. Option D (21-day doxycycline) is a defensible empiric choice for suspected LGV. However, Option E (moxifloxacin 400 mg daily for 14 days) is also a CDC-recommended alternative for LGV when doxycycline is contraindicated or not tolerated, making it a reasonable alternative best answer. The item is underspecified because without stating doxycycline intolerance/contraindication or providing LGV confirmation, both D and E are defensible. No internal contradictions. Medical accuracy: aligns with CDC STI guidelines that LGV requires 21-day doxycycline and moxifloxacin is an alternative. Minor issue: does not mention need for genotyping or HIV/MSM screening context. Minimal fix: Add clause 'Genotyping confirms L1 serovar' or 'Doxycycline is the preferred agent per guidelines' to eliminate Option E as a competitor.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-009", "question": "A 70-year-old man is evaluated for macrocytic anemia (MCV 105), thrombocytopenia, and recurrent inflammation of the ear and nose cartilage. He also has pulmonary infiltrates. Bone marrow biopsy demonstrates hypercellularity with vacuolization of myeloid and erythroid precursor cells. Genetic sequencing identifies a somatic mutation in *UBA1*. What is the diagnosis?", "options": ["Relapsing Polychondritis", "Myelodysplastic Syndrome (MDS)", "VEXAS Syndrome", "Sweet Syndrome", "Granulomatosis with Polyangiitis"], "answer": "C", "answer_index": 2, "explanation": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described disorder caused by somatic mutations in *UBA1*. It connects inflammatory features (polychondritis, vasculitis, infiltrates) with hematologic features (macrocytic anemia, vacuoles in marrow precursors). While it mimics relapsing polychondritis, the presence of marrow vacuoles and the *UBA1* mutation defines VEXAS.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem provides pathognomonic and hallmark features that uniquely identify VEXAS syndrome. Critical discriminators: (1) somatic UBA1 mutation is disease-defining; (2) bone marrow hypercellularity with vacuolization of both myeloid and erythroid precursors is a highly specific hematologic signature; (3) triad of macrocytic anemia, thrombocytopenia, and recurrent cartilage inflammation (ear/nose) combined with pulmonary infiltrates captures the syndrome's dual inflammatory-hematologic nature. Alternative options are correctly distractors: Relapsing polychondritis lacks cytopenias and marrow vacuoles; MDS does not cause inflammatory cartilage disease; Sweet syndrome features neutrophilic dermatosis without cartilage involvement or UBA1 mutation; Granulomatosis with polyangiitis causes granulomatous inflammation and cartilage destruction but not macrocytic anemia, thrombocytopenia, or marrow vacuolization. No internal contradictions or missing critical details. Medical accuracy: Fully consistent with seminal 2020 NEJM description and subsequent ACCR/EULAR recognition. The X-linked, somatic mosaic nature correctly explains late-onset presentation in males. All pathophysiologic and clinical features are accurately represented. Minimal fix: None required; item is board-exam ready.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides pathognomonic and hallmark features that uniquely identify VEXAS syndrome. Critical discriminators: (1) somatic UBA1 mutation is disease-defining; (2) bone marrow hypercellularity with vacuolization of both myeloid and erythroid precursors is a highly specific hematologic signature; (3) triad of macrocytic anemia, thrombocytopenia, and recurrent cartilage inflammation (ear/nose) combined with pulmonary infiltrates captures the syndrome's dual inflammatory-hematologic nature. Alternative options are correctly distractors: Relapsing polychondritis lacks cytopenias and marrow vacuoles; MDS does not cause inflammatory cartilage disease; Sweet syndrome features neutrophilic dermatosis without cartilage involvement or UBA1 mutation; Granulomatosis with polyangiitis causes granulomatous inflammation and cartilage destruction but not macrocytic anemia, thrombocytopenia, or marrow vacuolization. No internal contradictions or missing critical details. Medical accuracy: Fully consistent with seminal 2020 NEJM description and subsequent ACCR/EULAR recognition. The X-linked, somatic mosaic nature correctly explains late-onset presentation in males. All pathophysiologic and clinical features are accurately represented. Minimal fix: None required; item is board-exam ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-010", "question": "A 35-year-old female undergoes a cone biopsy for CIN 3. Pathology reveals invasive squamous cell carcinoma with 2 mm depth of invasion and 5 mm horizontal spread. Lymphovascular space invasion (LVSI) is extensively present. Margins are negative. Imaging shows no lymphadenopathy. She desires future fertility. According to NCCN guidelines, what is the recommended management?", "options": ["Simple trachelectomy", "Radical trachelectomy with pelvic lymph node assessment", "Conization with negative margins is sufficient", "Simple hysterectomy", "Pelvic radiation therapy"], "answer": "B", "answer_index": 1, "explanation": "The patient has Stage IA1 cervical cancer (invasion <= 3mm). However, the presence of Lymphovascular Space Invasion (LVSI) significantly increases the risk of lymph node metastasis and recurrence. Therefore, simple excision (cone) or simple trachelectomy/hysterectomy is insufficient. The recommended management for fertility preservation in IA1 with LVSI is radical trachelectomy with pelvic lymph node assessment (sentinel node or dissection).", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\":Validity label: K (Mis-keyed) – the key is not the best answer under current NCCN guidance. Verdict: Mis-keyed. Key stem clues: 35-year-old, CIN 3 → invasive SCC, depth 2 mm, horizontal spread 5 mm, extensive LVSI, negative margins, no lymphadenopathy, desires fertility. The depth of 2 mm places this in FIGO 2018 Stage IA1 (≤3 mm). NCCN 2024 guidelines state that for Stage IA1 with LVSI, the recommended treatment is a simple hysterectomy (or radical hysterectomy if additional risk factors) and that radical trachelectomy is NOT recommended because LVSI is a contraindication to fertility-sparing radical trachelectomy. The presence of extensive LVSI makes fertility-sparing surgery unsafe; standard care is simple hysterectomy (or radical hysterectomy). Therefore, Option D (simple hysterectomy) is the correct best answer, not Option B. Main logical issue: The keyed answer contradicts current guideline-based standard of care, making the item mis-keyed. Main medical accuracy issue: The rationale incorrectly states that radical trachelectomy is recommended for IA1 with LVSI; NCCN explicitly advises against fertility-sparing procedures in this setting. Minimal fix: Change the key to D and revise the rationale to reflect that LVSI is a contraindication to radical trachelectomy and that simple hysterectomy is the recommended management.\",\"logical_false_reason\":\"K\",\"logical_validity\":false,\"medical_accuracy_score\":\"2\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ":Validity label: K (Mis-keyed) – the key is not the best answer under current NCCN guidance. Verdict: Mis-keyed. Key stem clues: 35-year-old, CIN 3 → invasive SCC, depth 2 mm, horizontal spread 5 mm, extensive LVSI, negative margins, no lymphadenopathy, desires fertility. The depth of 2 mm places this in FIGO 2018 Stage IA1 (≤3 mm). NCCN 2024 guidelines state that for Stage IA1 with LVSI, the recommended treatment is a simple hysterectomy (or radical hysterectomy if additional risk factors) and that radical trachelectomy is NOT recommended because LVSI is a contraindication to fertility-sparing radical trachelectomy. The presence of extensive LVSI makes fertility-sparing surgery unsafe; standard care is simple hysterectomy (or radical hysterectomy). Therefore, Option D (simple hysterectomy) is the correct best answer, not Option B. Main logical issue: The keyed answer contradicts current guideline-based standard of care, making the item mis-keyed. Main medical accuracy issue: The rationale incorrectly states that radical trachelectomy is recommended for IA1 with LVSI; NCCN explicitly advises against fertility-sparing procedures in this setting. Minimal fix: Change the key to D and revise the rationale to reflect that LVSI is a contraindication to radical trachelectomy and that simple hysterectomy is the recommended management.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}]